External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home ESMO 2022
Roche and Genentech at

ESMO 2022

September 09 - September 13
Paris, France
esmo.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Highlights
Coming soon
10:15 AM
Duration 10mins 4.B – Brest Auditorium
IMmotion010: efficacy and safety from the Phase III study of atezolizumab vs placebo as adjuvant therapy in patients with renal cell carcinoma at increased risk of recurrence following resection
Bex A, Uzzo R, Karam JA, Master V, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann A, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Pal S
Oncology | Renal Cell Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 10mins 4.B – Brest Auditorium
PD-L1 Expression on Immune Cells by SP142 Co-LocalisesWith Dendritic Cells and is Associated With Improved Overall Survival with Atezolizumab in Patients With Untreated Metastatic Urothelial Cancer (mUC)
Grande E, Galsky MD, Van Elzen R, Banchereau R, Peterson M, Sedano C, Koeppen H, Li H, Bamias A, Arranz JA, Kikuchi E, De Santis M, Davis ID, Mellman I, Oh S, Williams P, Bernhard S, Lee C, Kockx M, Mariathasan S
Oncology | Urogenital Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
03:10 PM
Duration 5mins 7.2.E - Évry Auditorium
Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study
Martin M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz F, Safin R, Kim S, Schem C, Montero A, Khan S, Bandyopadhyay R, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Perez-Moreno P, Sohn J
Oncology | Breast Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:50 PM
Duration 10mins 7.3.O - Orléans Auditorium
MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors
Swanton C, Friedman CF, Spigel DR, Bose R, Burris HA, Levy J, Wang Y, Malato J, Price R, Darbonne W, Szado T, Schulze K, Sweeney CJ, Hainsworth J, Meric-Bernstam F, Kurzrock R
Oncology | Tumor Agnostic Biomarker Positive Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:20 PM
Duration 5mins 7.3.T - Toulouse Auditorium
Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
Manish R. Patel, Jong Seok Lee, Maria De Miguel, Timothy Burns, Alejandro Falcon, Tae Won Kim, Matthew G. Krebs, Hans Prenen, Einat Shacham-Shmueli, Jayesh Desai, Patricia LoRusso, Adrian Sacher, Yoonha Choi, Neekesh V. Dharia, Mark T. Lin, Sandhya Mandlekar, Stephanie Royer-Joo, Jennifer L. Schutzman, Elena Garralda
Oncology | Solid Tumours

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:40 PM
Duration 10mins 6.P - Paris Auditorium
IPSOS: Results from a Phase 3 study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Lee SM, Califano R, Cappuzzo F, Cortinovis D, Han B, Kumar P, Le AT, Liu G, Reck M, Reyes Contreras J, Rittmeyer A, Szczesna A, Vicente Baz D, Hu Youyou, Morris S, Hoglander E, Connors M, Vollan HK, Schulz C, Peters S
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: COVID-19
September 29
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Lung Cancer
September 29
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Breast cancer
September 30
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Melanoma
September 30
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Tumour agnostic therapies
October 04
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Gastrointestinal
October 04
Springer Healthcare
Open asset

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Tumour agnostic therapies
October 04
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Gastrointestinal
October 04
Springer Healthcare
Open asset

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: COVID-19
September 29
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Lung Cancer
September 29
Springer Healthcare
Open asset

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Breast cancer
September 30
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
European Society for Medical Oncology ESMO 2022 Annual Meeting: Melanoma
September 30
Springer Healthcare
Open asset

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.